论文部分内容阅读
目的探讨雷珠单抗玻璃体腔注射联合改良格栅样光凝治疗糖尿病黄斑水肿(DME)的疗效。方法非增殖期糖尿病视网膜病合并黄斑水肿患者40例(40眼)随机均分为两组:A组采用单纯改良黄斑格栅样光凝治疗;B组采用雷珠单抗玻璃体腔注射联合改良格栅样光凝治疗。治疗后2周和2个月随访,比较两组治疗后最佳矫正视力、眼压和黄斑中心厚度(CMT)变化。结果治疗后2周和2个月,A组和B组CMT均较治疗前下降(P<0.05),且B组CMT下降更明显(P<0.05)。治疗后2周和2个月,B组视力提高患者的比例高于A组(P<0.05),A组和B组眼压较治疗前均无显著改变(P>0.05)。两组治疗过程中均未发生明显不良反应。结论雷珠单抗联合改良格栅光凝治疗非增殖期DME较传统单纯激光治疗更为有效。
Objective To investigate the therapeutic effect of ranibizumab intravitreal injection combined with modified grid photocoagulation on diabetic macular edema (DME). Methods Forty patients (40 eyes) with non-proliferative diabetic retinopathy and macular edema were randomly divided into two groups: group A was treated with simple macular grid-like photocoagulation; group B was treated with intravitreal injection of ranibizumab combined with modified cell Gated photocoagulation. After 2 weeks and 2 months after treatment, the best corrected visual acuity, intraocular pressure and macular center thickness (CMT) were compared between the two groups after treatment. Results After 2 weeks and 2 months of treatment, the CMT in group A and group B decreased compared with that before treatment (P <0.05), and the CMT decreased more significantly in group B (P <0.05). At 2 weeks and 2 months after treatment, the visual acuity in group B was significantly higher than that in group A (P <0.05). The intraocular pressure in groups A and B were not significantly changed (P> 0.05). No significant adverse reactions occurred in both groups during the course of treatment. Conclusion The combination of ranibizumab and modified grid photocoagulation is more effective in the treatment of non-proliferative DME than conventional laser therapy alone.